The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from federal drug shortage list amid intense pushback from compounded drug manufacturers.

Weight loss jab tirzepatide – commonly sold under the brand name Mounjaro – is set to become available via the NHS for eligible patients in England.

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.